Jiangzhi Granule Ameliorates JNK-Mediated Mitochondrial Dysfunction to Reduce Lipotoxic Liver Injury in NASH by Jiang Y, Xu J, Ding J, Liu T, Liu Y, Huang P, Wang Q, Zheng P, Song H, Yang L

“…Additionally, elevated phosphorylation ratio of non-receptor tyrosine kinase c-Src (Src) and reduced phosphorylation ratio of JNK and SH2-containing protein tyrosine phosphatase (SHP-1) were found in both hepatocytes and mice liver tissues treated with JZG versus those with the vehicle.Conclusion: Taken together, JZG could improve mitochondrial dysfunction and reduce lipotoxic liver injury in NASH in vivo and in vitro models. …”
Get full text

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer... by Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura

“…Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK‐TKIs) via emergence of a subpopulation of drug‐tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberrations. …”
Get full text

Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor by Baojie Liu, Yongzheng Lu, Ruihui Lin, Junbao Xu, Zilin Shang, Xinyu Hou, Xulong Shao, Zhifang Pan, Tao Yu, Weiguo Feng

“…As a result, it is crucial to discover effective medications against ABCB1 to overcome MDR. Falnidamol, a tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), is currently in phase 1 clinical trials for the treatment of solid tumors. …”
Get full text

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia by Olivia M. Depies, Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G. Rabe, Mingma S. Hoel, Heather C. Darby, Chuanhe Yu, Esteban Braggio, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Zhiquan Wang

“…Finally, when treated with the Bruton tyrosine kinase inhibitor ibrutinib, these silenced enhancers are relatively stable during therapy compared with the CLL-gained enhancers. …”
Get full text

Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia by Igor Belenichev, Olena Popazova, Oleh Yadlovskyi, Nina Bukhtiyarova, Victor Ryzhenko, Sergii Pavlov, Valentyn Oksenych, Oleksandr Kamyshnyi

“…Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 in the heart’s cytosolic homogenate were assessed using ELISA. …”
Get full text

Comparison of tissue-based and plasma-based testing for mutation in non–small cell lung cancer patients by Yoon Kyung Kang, Dong Hoon Shin, Joon Young Park, Chung Su Hwang, Hyun Jung Lee, Jung Hee Lee, Jee Yeon Kim, JooYoung Na

“…Background Epidermal growth factor receptor (EGFR) gene mutation testing is crucial for the administration of tyrosine kinase inhibitors to treat non–small cell lung cancer. …”
Get full text

STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC by Shiyu Huang, Xuke Qin, Shujie Fu, Juncheng Hu, Zhengyu Jiang, Min Hu, Banghua Zhang, Jiachen Liu, Yujie Chen, Minghui Wang, Xiuheng Liu, Zhiyuan Chen, Lei Wang

“…Furthermore, STAMBPL1 silencing and the tyrosine kinase inhibitor (TKI) sunitinib also exhibited a synergistic effect on the suppression of KIRC. …”
Get full text

Ewing sarcoma – pathomechanisms, standard treatment and new therapeutic perspectives by Wojciech Zezuliński, Filip Woliński, Julia Zyśk, Mateusz Korga, Jakub Klas, Jacek Baj, Eliasz Dzierżyński

“…The paper discusses, among other things, treatment attempts based on the role of the EWS-FLI1 protein, epigenetics, tyrosine kinase inhibitors, immunotherapies and the use of nanomedicine and viruses, as well as the difficulties associated with their application. …”
Get full text

Secondary prevention of preeclampsia by Muhammad Ilham Aldika Akbar, Muhammad Ilham Aldika Akbar, Roudhona Rosaudyn, Khanisyah Erza Gumilar, Khanisyah Erza Gumilar, Renuka Shanmugalingam, Gustaaf Dekker, Gustaaf Dekker

“…Proton pump inhibitors (PPIs) have shown potential in lowering soluble FMS-like tyrosine kinase-1 (sFlt-1) levels and enhancing endothelial function, but clinical trials have been inconsistent. …”
Get full text

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy by Meng-Tung Hsu, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky, Leo Hansmann, Leo Hansmann, Leo Hansmann, Leo Hansmann, Thomas Blankenstein

“…BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. …”
Get full text

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases by Kazuhiro Usui, Tomonori Ushijima, Yoshiaki Tanaka, Chiharu Tanai, Hiromichi Noda, Norifumi Abe, Hajime Horiuchi, Teruo Ishihara

“…Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). …”
Get full text

Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO by Vidya Narayanaswami PhD, Kenneth Dahl PhD, Vadim Bernard-Gauthier PhD, Lee Josephson PhD, Paul Cumming PhD, Neil Vasdev PhD

“…We now review the lead structures in radiotracer development for PET studies of neuroinflammation targets for neurodegenerative diseases extending beyond TSPO, including glycogen synthase kinase 3, monoamine oxidase-B, reactive oxygen species, imidazoline-2 binding sites, cyclooxygenase, the phospholipase A2/arachidonic acid pathway, sphingosine-1-phosphate receptor-1, cannabinoid-2 receptor, the chemokine receptor CX3CR1, purinergic receptors: P2X 7 and P2Y 12 , the receptor for advanced glycation end products, Mer tyrosine kinase, and triggering receptor expressed on myeloid cells-1. …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

“…Abstract The crosstalk between cancers and the immune microenvironment plays a critical role in malignant progression. FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML). …”
Get full text

EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report by Hiroyuki Fujii, MD, Yusuke Okuma, MD, PhD, Makoto Hirata, MD, PhD, Yuki Shinno, MD, PhD, Tatsuya Yoshida, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Yuichiro Ohe, MD, PhD

“…Remarkably, despite the presence of EGFR mutation, the response to EGFR-tyrosine kinase inhibitor was poor, whereas the response to cytotoxic anticancer drugs and immunotherapy was favorable. …”
Get full text

Molecular Alterations of KIT Oncogene in Gliomas by Ana L. Gomes, Jorge S. Reis-Filho, José M. Lopes, Olga Martinho, Maryou B. K. Lambros, Albino Martins, Fernando Schmitt, Fernando Pardal, Rui M. Reis

“…KIT, a class III receptor tyrosine kinase (RTK), is frequently involved in tumourigenic processes. …”
Get full text

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity by Daniela Di Lisi, Cristina Madaudo, Giulia Alagna, Marco Santoro, Ludovico Rossetto, Sergio Siragusa, Giuseppina Novo

“…Abstract Aims Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. …”
Get full text

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort by Hilin Yildirim, Anke Richters, Adriaan D. Bins, Arnoud W. Postema, Maureen J.B. Aarts, Martijn G.H. van Oijen, Patricia J. Zondervan, Katja K.H. Aben

“…Targeted therapy with tyrosine kinase inhibitors (TKIs) was the standard of care for metastatic renal cell carcinoma (mRCC) until recently, when new first-line combinations with immuno-oncology (IO) agents were approved. …”
Get full text

lncRNA HHIP-AS1 Promotes the Osteogenic Differentiation Potential and Inhibits the Migration Ability of Periodontal Ligament Stem Cells by Qianyi Qin, Haoqing Yang, Chen Zhang, Xiao Han, Jing Guo, Zhipeng Fan, Jie Guo

“…In addition, the RNA sequencing data showed that 356 mRNAs and 14 lncRNAs were upregulated, including receptor tyrosine kinase-like orphan receptor 2 and nuclear-enriched abundant transcript 1, while 185 mRNAs and 6 lncRNAs were downregulated, including fibroblast growth factor 5 and LINC00973, in HHIP-AS1-depleted PDLSCs. …”
Get full text

Relapsing Campylobacter jejuni Systemic Infections in a Child with X-Linked Agammaglobulinemia by Paola Ariganello, Giulia Angelino, Alessia Scarselli, Irene Salfa, Martina Della Corte, Arianna De Matteis, Patrizia D'Argenio, Susanna Livadiotti, Emma C. Manno, Cristina Russo, Andrea Finocchi, Caterina Cancrini

“…X-linked agammaglobulinemia (XLA) is a primary immunodeficiency of the humoral compartment, due to a mutation in the Bruton tyrosine kinase (BTK) gene, characterized by a severe defect of circulating B cells and serum immunoglobulins. …”
Get full text

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients by Umberto Basile, Mariapaola Marino, Cecilia Napodano, Krizia Pocino, Paolo Emilio Alboini, Francesca Gulli, Amelia Evoli, Carlo Provenzano, Emanuela Bartoccioni

“…Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction with antibodies (abs) targeting the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK), inducing muscle weakness and excessive fatigability. …”
Get full text